Zentraxa is precision engineering biomaterials, pushing the boundaries of biopolymer synthesis to develop sustainable, performance-enhancing ingredients for everyday products. Its proprietary technological platform (Zentide) overcomes the biodesign limits of existing, conventional peptide synthesis by designing, producing and testing complex, novel peptides with one universal process. Zentraxa creates bespoke solutions for a range of industries by combining key features from different naturally-occurring proteins, such as stiffness, adhesion or thermal stability.

Hone Bio is revolutionising drug delivery using lipid nanoparticles (LNPs) and exploring their potential across multiple therapeutics, including cell and gene therapies, vaccines and autoimmune diseases. Its NanoPilot platform technology engineers LNPs to target specific cell types with extreme precision to optimise drug effectiveness by minimising off-target effects that tend to accumulate in the liver. This unlocks new possibilities for using LNPs to safely treat diseases in other parts of the body that require maximum target specificity in their drug delivery.

Scarlet Therapeutics is developing a proprietary platform that generates novel red blood cell-based therapeutics (tRBCs) to treat a wide range of diseases. Its technologies are underpinned by learnings from decades of research including the groundbreaking RESTORE clinical study run by NHS Blood and Transplant and the University of Bristol, investigating transfusion of lab-grown blood into patients. By generating tRBCs with high levels of therapeutic proteins from cell lines rather than from donated stem cells, Scarlet Therapeutics aims to address significant efficacy and manufacturing issues faced in the field.

neo-fossil is developing new technology using cell engineering to help reverse the threat of climate change. By optimising biology, it is creating new fossils that harvest atmospheric carbon dioxide, storing it for centuries.

Folium Science is increasing agricultural productivity by enhancing animal welfare and feed efficiency in livestock farming while reducing environmental impact. Its unique CRISPR-Cas technology platform harnesses natural biological systems to safely modulate animal microbiomes by regulating metabolic functions and targeting unwanted bacteria with extreme precision. This approach helps reduce reliance on antibiotics and can be applied to both plants and soil to improve their bacterial biomes for optimal growing conditions.

Reach Industries is optimising lab and scientist efficiency with its Lumi™ visual intelligence platform. By automating data capture and analysis for experiments, observations and complex scientific workflows, the platform functions as a streamlined operating system that is accelerating R&D, improving compliance and increasing reproducibility.